28 November 2019

Achilles Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference


Stevenage, UK 28 November 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announced that Dr. Iraj Ali, Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference at the Lotte New York Palace in New York City on Wednesday, December 4, 2019 at 11:30 am ET.

– Ends –

About Achilles Therapeutics

Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient, together with the proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop personalised T cell-based therapies specifically targeting those clonal neoantigens.

Achilles was founded in 2016 by lead investor Syncona Ltd and in September 2019 the Company raised £100M in an oversubscribed Series B financing led by RA Capital, cornerstoned by Syncona and joined by new investors including Forbion, Invus, Perceptive Advisors and Redmile Group. For further information please visit the Company’s website at: www.achillestx.com


Further information:


Achilles Therapeutics
Dr Iraj Ali – Chief Executive Officer
+44 (0)1438 906 906


Julia Wilson – Head of Communications
+44 (0)7818 430877


Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
Tel: +44 (0) 203 709 5000
Email: achillestx@consilium-comms.com


US Investor Relations - Solebury Trout
Lee Stern
+1 646-378-2922



Back to previous page